Anesthesia for Kearns Sayre syndrome

case report

Authors

DOI:

https://doi.org/10.29327/2457362.65.66-2

Keywords:

Chronic progressive external ophthalmoplegia, Kearns-sayre syndrome, Propofol

Abstract

Introduction: Introduction: Kearns-Sayre syndrome (KSS) is a very rare multisystem mitochondrial disease that occurs before the age of 20 and is characterized by a typical clinical triad: progressive external ophthalmoplegia with ptosis, pigmentary retinopathy and cardiac conduction abnormalities, including heart block. Other clinical manifestations may also include muscle weakness, symptoms of neurological dysfunction such as cerebellar ataxia, impaired intellectual and cognitive function, sensorineural hearing loss and neuropathy, various endocrine abnormalities, nephropathy, and dental anomalies. Case Report: Female patient, 62 years old, with heart disease using a bicameral pacemaker, type II diabetic, sedentary, with KSS, was admitted in Goiânia, Goiás on 05/06/2024 after desaturation and decreased level of consciousness, being diagnosed with pneumonia in the emergency room. She was intubated and maintained on mechanical ventilation until May 16th and then a tracheostomy (TQT) was performed. After the TQT, the patient was already in the infirmary bed (with TQT in a tent) where the patient’s pulmonary investigation was continued with bronchoscopy under light sedation (midazolam, propofol and fentanyl). After the procedure, the patient was kept in the post-anesthesia recovery room for approximately sixty minutes and taken to the infirmary bed. Approximately six hours after bronchoscopy, the patient began to experience desaturation, cyanosis of the extremities and central region, and a lower level of consciousness. She was taken to the ICU and maintained on BIPAP support. Bronchoscopy result was negative. During her stay in the ICU, she was diagnosed with two bacterial pneumonias and one viral pneumonia due to Influenza A. The TQT was changed on 06/04/24 and 06/17/24. On 06/19/24, the patient underwent gastrostomy under light sedation using fentanyl 15 mcg, midazolam 3 mg, ketamine 5 mcg without complications and was subsequently sent to the ICU, where she remained without adverse events. Discussion: KSS is a rare mitochondrial disease that is difficult to diagnose early. Little is known about the behavior of the disease in the face of surgical procedures, which is why it is a challenge. In patients diagnosed with KSS, toxic mitochondrial medications should be avoided, such as propofol, aminoglycosides, linezolin, metformin and nucleoside analogues.

References

Guo L, Wang X, Ji H. Clinical phenotype and genetic features of a pair of chinese twins with kearns-sayre syndrome. DNA Cell Biol [Internet]. 2020 Aug [Cited 2024 Oct 31];39(8):1449-47. doi: 10.1089/dna.2019.5010

Luca P, Alessia G, Camilla RM, Antonio N, Diego M, Federica D, Daria D, Rosalba C, Carlo DV, Daniela L. Spinal cord involvement in kearns- -sayre syndrome: a neuroimaging study. Neuroradiology [Internet]. 2020 Oct [Cited 2024 Oct 31];62(10):1315-21. doi: 10.1007/s00234-020- 02501-0

Gross-Jendroska M, Schatz H, McDonald HR, Johnson RN. Kearns-sayre syndrome: a case report and review. Eur J Ophthalmol [Internet]. 1992 Jan-Mar [Cited 2024 Oct 31];2(1):15-20. doi: 10.1177/112067219200200104

Maceluch JA, Niedziela M. The clinical diagnosis and molecular genetics of kearns-sayre syndrome: a complex mitochondrial encephalomyopathy. Pediatr Endocrinol Rev. 2006 Dec-2007 Jan;4(2):117-37.

D’Erchia AM, Atlante A, Gadaleta G, Pavesi G, Chiara M, De Virgilio C, Manzari C, Mastropasqua F, Prazzoli GM, Picardi E, Gissi C, Horner D, Reyes A, Sbisà E, Tullo A, Pesole G. Tissue-specific mtDNA abundance from exome data and its correlation with mitochondrial transcription, mass and respiratory activity. Mitochondrion [Internet]. 2015 Jan [Cited 2024 Oct 31];20:13-21. doi: 10.1016/j.mito.2014.10.005

Satoh M, Kuroiwa T. Organization of multiple nucleoids and DNA molecules in mitochondria of a human cell. Exp Cell Res [Internet]. 1991 Sep [Cited 2024 Oct 31];196(1):137-40. doi: 10.1016/0014-4827(91)90467-9

Kierdaszuk B, Kaliszewska M, Rusecka J, Kosińska J, Bartnik E, Tońska K, Kamińska AM, Kostera-Pruszczyk A. Progressive external ophthalmoplegia in polish patients-from clinical evaluation to genetic confirmation. Genes (Basel) [Internet]. 2020 Dec 31 [Cited 2024 Oct 31];12(1):54. doi: 10.3390/genes12010054

Olson W, Engel WK, Walsh GO, Einaugler R. Oculocraniosomatic neuromuscular disease with “ragged-red” fibers. Arch Neurol [Internet]. 1972 Mar [Cited 2024 Oct 31];26(3):193-211. doi: 10.1001/archneur.1972.00490090019001

Kisilevsky E, Freund P, Margolin E. Mitochondrial disorders and the eye. Surv Ophthalmol [Internet]. 2020 May-Jun [Cited 2024 Oct 31];65(3):294-311. doi: 10.1016/j.survophthal.2019.11.001

Leal M, Dhoble C, Lee J, Lopez D, Menéndez LS. A rare case of kearns-sayre syndrome in a 17-year-old venezuelan male with bilateral ptosis as the initial presentation. Oxf Med Case Reports [Internet]. 2016 Mar 3 [Cited 2024 Oct 31];2016(3):34-6. doi: 10.1093/omcr/omw007

Pitceathly RD, Rahman S, Hanna MG. Single deletions in mitochondrial DNA-molecular mechanisms and disease phenotypes in clinical practice. Neuromuscul Disord [Internet]. 2012 Jul [Cited 2024 Oct 31];22(7):577-86. doi: 10.1016/j.nmd.2012.03.009

Yamashita S, Nishino I, Nonaka I, Goto YI. Genotype and phenotype analyses in 136 patients with single large-scale mitochondrial DNA deletions. J Hum Genet [Internet]. 2008 [Cited 2024 Oct 31];53(7):598. doi: 10.1007/s10038-008-0289-8

Hung KM, Chen PC, Hsieh HC, Calkins MJ. Mitochondrial defects arise from nucleoside/nucleotide reverse transcriptase inhibitors in neurons: potential contribution to HIV-associated neurocognitive disorders. Biochim Biophys Acta Mol Basis Dis [Internet]. 2017 Feb [Cited 2024 Oct 31];1863(2):406-13. doi: 10.1016/j.bbadis.2016.11.017

Orsucci D, Ienco EC, Siciliano G, Mancuso M. Mitochondrial disorders and drugs: what every physician should know. Drugs Context [Internet]. 2019 Jul 4 [Cited 2024 Oct 31];8:212588. doi: 10.7573/dic.212588

Maddali MM, Munasinghe TD, Al Aamri I, Al-Abri IA, Al-Adawi S. Propofol and kearns-sayre syndrome: an idiographic approach. Sultan Qaboos Univ Med J [Internet]. 2023 Dec [Cited 2024 Oct 31];23(Spec Iss):63-7. doi: 10.18295/squmj.12.2023.080

Finsterer J, Frank M. Propofol is mitochondrion-toxic and may unmask a mitochondrial disorder. J Child Neurol [Internet]. 2016 Nov [Cited 2024 Oct 31];31(13):1489-94. doi: 10.1177/0883073816661458

Published

2024-11-13

How to Cite

1.
Silva MF de S, Pacheco DC, Elmiro GS, Gardenghi G. Anesthesia for Kearns Sayre syndrome: case report. Rev Goiana Med [Internet]. 2024 Nov. 13 [cited 2026 May 28];65(66):1-5. Available from: https://amg.org.br/osj/index.php/RGM/article/view/234